Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of neonatal BCG on immunogenicity of serogroup C meningococcal conjugate vaccine in infants
2013-003488-71Phase 4Completed
- Sponsor
- University of Oxford
- Start
- Dec 2013
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bacillus calmette-guerin substrain danish 1331 live antigen in Serogroup C meningococcal disease (MenC) (2 arms), sponsored by University of Oxford. Primary endpoint: MenC-specific IgG concentration at 8 weeks after MenC vaccination. Started Dec 2013; status: completed.
02
Drugs
bacillus calmette-guerin substrain danish 1331 live antigen
03
Conditions
Serogroup C meningococcal disease (MenC)
Beyond the preview
Go deeper on 2013-003488-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003488-71.